PE20030433A1 - Formulacion liquida que comprende cetuximab - Google Patents

Formulacion liquida que comprende cetuximab

Info

Publication number
PE20030433A1
PE20030433A1 PE2002000618A PE2002000618A PE20030433A1 PE 20030433 A1 PE20030433 A1 PE 20030433A1 PE 2002000618 A PE2002000618 A PE 2002000618A PE 2002000618 A PE2002000618 A PE 2002000618A PE 20030433 A1 PE20030433 A1 PE 20030433A1
Authority
PE
Peru
Prior art keywords
liquid formulation
polyoxyethylene
formulation including
including cetuximab
cetuximab
Prior art date
Application number
PE2002000618A
Other languages
English (en)
Inventor
Christiane Bachmann
Udo Haas
Robert Muller
Ulrike Martini-Marr
Hanns Christian Mahler
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PE20030433A1 publication Critical patent/PE20030433A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Abstract

SE REFIERE A UNA FORMULACION FARMACEUTICA LIQUIDA QUE COMPRENDE: a) EL ANTICUERPO MONOCLONAL QUIMERICO C225 ( CETUXIMAB ) CONTRA EL RECEPTOR DEL FACTOR DE CRECIMIENTO ENDOTELIAL (RECEPTOR EGF) ; b) DE 2mM A 100 mM DE UN BUFFER FOSFATO Y c) DE 0,005% A 0,1% DE UN ESTER DE ACIDO GRASO DE POLIOXIETILEN SORBITAN SELECCIONADO DE MONOOLEATO DE POLIOXIETILEN (20) SORBITAN O MONOLAURATO DE POLIOXIETILEN (20) SORBITAN. LA FORMULACION TIENE UN pH ENTRE 6,5 A 7,5 Y CONTIENE ADEMAS UN AGENTE ISOTONICO TAL COMO CLORURO DE SODIO
PE2002000618A 2001-07-13 2002-07-11 Formulacion liquida que comprende cetuximab PE20030433A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10133394A DE10133394A1 (de) 2001-07-13 2001-07-13 Flüssige Formulierung enthaltend Cetuximab

Publications (1)

Publication Number Publication Date
PE20030433A1 true PE20030433A1 (es) 2003-05-24

Family

ID=7691220

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000618A PE20030433A1 (es) 2001-07-13 2002-07-11 Formulacion liquida que comprende cetuximab

Country Status (18)

Country Link
US (1) US20040170632A1 (es)
EP (1) EP1406658A1 (es)
JP (1) JP2004536129A (es)
KR (1) KR20040018458A (es)
CN (1) CN1231264C (es)
AR (1) AR039358A1 (es)
BR (1) BR0211060A (es)
CA (1) CA2453342A1 (es)
CZ (1) CZ2004189A3 (es)
DE (1) DE10133394A1 (es)
HU (1) HUP0401046A3 (es)
MX (1) MXPA04000340A (es)
PE (1) PE20030433A1 (es)
PL (1) PL364599A1 (es)
RU (1) RU2004102395A (es)
SK (1) SK862004A3 (es)
WO (1) WO2003007988A1 (es)
ZA (1) ZA200401161B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3417875T3 (da) * 2003-02-10 2020-08-31 Biogen Ma Inc Immunglobulinformulering og fremgangsmåde til fremstilling deraf
DE10355251A1 (de) * 2003-11-26 2005-06-23 Merck Patent Gmbh Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
DE10355904A1 (de) 2003-11-29 2005-06-30 Merck Patent Gmbh Feste Formen von anti-EGFR-Antikörpern
AU2005211890B2 (en) * 2004-02-12 2011-07-28 Merck Patent Gmbh Highly concentrated liquid formulations of anti-EGFR antibodies
MXPA06012145A (es) * 2004-04-27 2007-01-31 Wellstat Biologics Corp Tratamiento del cancer utilizando virus y camptotecinas.
JP2008519757A (ja) * 2004-11-12 2008-06-12 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 抗ｅｇｆｒ抗体の固形物
CN101163468A (zh) * 2005-02-28 2008-04-16 卫材R&D管理有限公司 磺酰胺化合物的新联合用途
NZ570381A (en) 2006-02-09 2011-02-25 Daiichi Sankyo Co Ltd Anti-cancer pharmaceutical composition
WO2007128557A1 (en) 2006-05-03 2007-11-15 Bayer Schering Pharma Aktiengesellschaft Combination of an anti edb fibronectin domain antibody l19-sip and an anti-egfr antibody
AU2007307107B2 (en) * 2006-10-06 2011-11-03 Amgen Inc. Stable antibody formulations
TW200833357A (en) * 2006-10-20 2008-08-16 Amgen Inc Stable polypeptide formulations
CN107773755B (zh) * 2016-08-31 2021-06-22 上海津曼特生物科技有限公司 抗表皮生长因子受体单克隆抗体的注射液制剂
WO2018211517A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
KR20210024082A (ko) 2018-06-25 2021-03-04 제이씨알 파마 가부시키가이샤 단백질 함유 수성 액제

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) * 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5945098A (en) * 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
JPH11507535A (ja) * 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
PT1516628E (pt) * 1995-07-27 2013-09-24 Genentech Inc Formulação de proteína liofilizada isotónica estável

Also Published As

Publication number Publication date
HUP0401046A2 (en) 2006-04-28
BR0211060A (pt) 2004-07-20
MXPA04000340A (es) 2004-05-04
AR039358A1 (es) 2005-02-16
KR20040018458A (ko) 2004-03-03
HUP0401046A3 (en) 2006-11-28
DE10133394A1 (de) 2003-01-30
CA2453342A1 (en) 2003-01-30
EP1406658A1 (de) 2004-04-14
SK862004A3 (en) 2004-07-07
PL364599A1 (en) 2004-12-13
ZA200401161B (en) 2004-10-22
US20040170632A1 (en) 2004-09-02
WO2003007988A1 (de) 2003-01-30
CN1527724A (zh) 2004-09-08
JP2004536129A (ja) 2004-12-02
CZ2004189A3 (cs) 2004-05-12
RU2004102395A (ru) 2005-05-27
CN1231264C (zh) 2005-12-14

Similar Documents

Publication Publication Date Title
PE20030433A1 (es) Formulacion liquida que comprende cetuximab
PE20090738A1 (es) Formulaciones de anticuerpos
AU3438900A (en) Use of trehalose for stabilising a liquid vaccine
CO5660273A2 (es) Formulaciones de proteina y anticuerpo de alta concentracion
MA27551A1 (fr) Composition immunogene
JO2481B1 (en) Silo cano-indol compounds have fluoride substitution and formulations containing such compounds and their treatment methods
IL153406A0 (en) Cyclopentanoindoles, compositions containing such compounds and methods of treatment
UY26704A1 (es) Nueva composición farmacéutica
MX275023B (es) Champu que contiene una red de gel.
ATE485835T1 (de) Antikörper enthaltende pharmazeutische lösungen
ES2143507T3 (es) Vacunas contra la enfermedad de aujeszky y de otras enfermedades animales que contienen mutantes del virus de la pseudorrabia.
NL980012I2 (nl) Mometasonfuroaat-monohydraat, werkwijze om zulks te bereiden en farmaceutische samenstellingen.
ES2194989T3 (es) Composicion adminstrada por via oral, que comprende una toxina de zonula occludens y un agente que tiene una actividad biologica, y su utilizacion.
NO20014101L (no) Stabilisert oral farmasöytisk blanding inneholdende iodid og iodat og fremgangsmåte
AU2019339740A8 (en) CSF-1R antibody formulation
CL2009001680A1 (es) Composiciones agroquimicas que comprenden a)metconazol o una sal del mismo y b)un acido carboxilico alifatico de cadena lineal o ramificada, saturado o no saturado y donde la relacion molar de (b) respecto de (a) es superior a 1
ES2182255T3 (es) Agente de blanqueo fluorescente.
MX2021010951A (es) Composición líquida que comprende un anticuerpo del receptor alfa de interleucina-4 humano.
CA2498233A1 (en) Clear ophthalmic solution comprising latanoprost as active ingredient
ATE502647T1 (de) Zubereitungen enthaltend sincalide
BRPI0017528B8 (pt) uso de uma composição contendo sal de cetotifeno
EP1509250A4 (en) METHOD, COMPOSITIONS AND PRODUCTION OBJECTS FOR MODULATING BONE GROWTH
BR0304218A (pt) ésteres alicìclicos com fragrância de almìscar
WO2007006581A3 (en) Targeting lsd1 for use in identifying and/or scoring prostate cancer and for controlling anrogen receptor-dependent gene expression
HUP0300240A2 (hu) Polikarbonáttartalmú készítmények

Legal Events

Date Code Title Description
FD Application declared void or lapsed